Update on the cardiovascular profile of fingolimod in the therapy of relapsing-remitting multiple sclerosis (MS).

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Multiple Sclerosis and Related Disorders

• Publication date

  2016-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.msard.2016.04.002PMID 27456870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of British Neurologists: revised (2015) guidelines for prescribing disease-modifying treatments in multiple sclerosis

  2015cited by this paper
• Long-term Safety of Fingolimod: An Interim Analysis of the LONGTERMS Cohort (S4.006)

  2015cited by this paper
• Original InvestigationEditorial CommentVentricular Ectopy as a Modifiable Risk Factor for Heart Failure and Death: “Déjà Vu All Over Again” May Be a Good Thing∗

  2015cited by this paper
• Long-term effects of fingolimod in multiple sclerosis

  2015cited by this paper
• Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Vagomimetic Effects of Fingolimod: Physiology and Clinical Implications

  2014cited by this paper
• Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial

  2014cited by this paper
• Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 1 historical and established therapies. MS Neurology Group of the Australian and New Zealand Association of Neurologists.

  2014cited by this paper
• First-dose effects of fingolimod: Pooled safety data from three phase 3 studies.

  2014cited by this paper
• Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis

  2014cited by this paper
• Cardiac Effects of Fingolimod after First Dose Administration and Therapy Change in Patients with Multiple Sclerosis (P01.170)

  2013cited by this paper
• Assessment of cardiac safety during fingolimod treatment initiation in a real-world relapsing multiple sclerosis population: a phase 3b, open-label study

  2013cited by this paper
• Treatment Optimization in MS: Canadian MS Working Group Updated Recommendations

  2013cited by this paper
• Sphingosine-1-phosphate signaling and its role in disease.

  2012cited by this paper
• Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study.

  2011cited by this paper
• A mechanistically novel, first oral therapy for multiple sclerosis: the development of fingolimod (FTY720, Gilenya).

  2011cited by this paper
• A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis.

  2010cited by this paper
• Sphingosine 1-Phosphate (S1P) Regulates Vascular Contraction via S1P3 Receptor: Investigation Based on a New S1P3 Receptor Antagonist

  2010cited by this paper
• Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

  2010cited by this paper
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis

  2010cited by this paper
• FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

  2009cited by this paper
• G Protein-Activated (GIRK) Current in Rat Ventricular Myocytes is Masked by Constitutive Inward Rectifier Current (IK1)

  2008cited by this paper
• Analysis of sphingosine 1‐phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools

  2008cited by this paper
• Modulation of T cell homeostasis and alloreactivity under continuous FTY720 exposure.

  2008cited by this paper
• FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

  2008cited by this paper
• Effects of LPA and S1P on the nervous system and implications for their involvement in disease.

  2007cited by this paper
• Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology.

  2007influential reference
• Lysophospholipid receptors: signalling, pharmacology and regulation by lysophospholipid metabolism.

  2007cited by this paper
• ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines

  2006cited by this paper
• The Heart Rate Decrease Caused by Acute FTY720 Administration Is Mediated by the G Protein‐Gated Potassium Channel IKACh

  2005cited by this paper
• Physiology and pharmacology of the cardiac pacemaker ("funny") current.

  2005cited by this paper
• Endothelial cell barrier regulation by sphingosine 1‐phosphate

  2004cited by this paper
• Sphingosine 1-Phosphate (S1P) Receptor Subtypes S1P1 and S1P3, Respectively, Regulate Lymphocyte Recirculation and Heart Rate*

  2004cited by this paper
• Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension

  1997cited by this paper
• Activation of muscarinic K+ current in guinea‐pig atrial myocytes by sphingosine‐1‐phosphate.

  1995cited by this paper
• Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases.

  1989cited by this paper
• Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy.

  1986cited by this paper
• Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy.

  1985cited by this paper

• Discovery and SAR study of highly selective and potent 1,2,4-oxadiazole-based S1PR1 agonists.

  2025cites this paper
• Novel Finding of Retinal Aneurysmal Alterations in Patients Undergoing Fingolimod Therapy for Multiple Sclerosis

  2025cites this paper
• The potential capacities of FTY720: Novel therapeutic functions, targets, and mechanisms against diseases.

  2025cites this paper
• A Brief Review of Multiple Sclerosis Treatments

  2022cites this paper
• Is there a connection between HDL and atrial fibrillation?

  2022cites this paper
• Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis

  2021cites this paper
• Anti-inflammatory Efficacy of Combined Natural Alkaloid Berberine and S1PR Modulator Fingolimod at Low Doses in Ulcerative Colitis Preclinical Models.

  2020cites this paper
• Prevention and management of adverse effects of disease modifying treatments in multiple sclerosis.

  2020cites this paper
• Sphingosine 1-Phosphate Receptor Modulator ONO-4641 Regulates Trafficking of T Lymphocytes and Hematopoietic Stem Cells and Alleviates Immune-Mediated Aplastic Anemia in a Mouse Model

  2020cites this paper
• Immunological Aspects of Approved MS Therapeutics

  2019cites this paper
• Are there any clinical and electrocardiographic predictors of heart rate reduction in relapsing- remitting multiple sclerosis patients treated with fingolimod?

  2019cites this paper
• Managing Risks with Immune Therapies in Multiple Sclerosis

  2019cites this paper
• Fingolimod in multiple sclerosis: profile of use in habitual practice

  2019cites this paper
• Risks and risk management in modern multiple sclerosis immunotherapeutic treatment

  2019cites this paper
• Is there a role for therapeutic sphingolipids in inflammatory bowel disease?

  2019cites this paper
• Fingolimod-induced decrease in heart rate may predict subsequent decreasing degree of lymphocytes

  2018cites this paper
• Multiple sclerosis treatment with fingolimod: profile of non-cardiologic adverse events

  2017cites this paper
• Modulation of sphingosine-1-phosphate in inflammatory bowel disease.

  2017cites this paper
• Next generation of small molecules in inflammatory bowel disease

  2016cites this paper
• Editors' Welcome.

  2016cites this paper
• What is the future of proof of concept studies in multiple sclerosis?

  2016cites this paper